|
|
Curriculum Vitae
Henry G. GrabowskiClick here for a printer-ready version, or
download as a PDF file.-
| Box 90097, Durham, NC 27708-0097
|
 (email)
|
- Education
| Ph.D. | Princeton University | 1967 |
| M.A. | Princeton University | 1964 |
| B.S. | Lehigh University | 1962 |
- Areas of Research
Economics of Innovation, Governmental Regulation of Business, and Economics of Pharmaceutical Industry
- Professional Experience / Employment History
- Duke University
- Director, Program in Pharmaceuticals and Health Economics, 1983-present
-
- Professor, Department of Economics, 1976-present
-
- Associate Professor, Department of Economics, 1972-1976
- International Institute of Management
- Research Fellow, , 1976
- National Bureau of Economic Research
- Research Associate, , 1971-1972
- Yale University
- Assistant Professor, Department of Economics, 1967-1971
- Visiting Positions
- Visiting Scholar, Health Care Financing Administration, 1979-1980
- Publications (listed separately)
- Professional Service
- A&S Council
- Academic Priorities Committee, 2000-2003
- Arts and Science Council, 2003-2004
- Staff Benefits, 2000-2002
- University Committee
- Member, Faculty Compensation Committee, 2003-2004
- Dept Committee
- Member, Editorial Committee for Departmental Newsletter, 2002-2003
- Member, Computerizing Database on Faculty Performance, 2002-2003
- Papers Refereed
- "Quarterly Review of Economics and Finance" and "Journal of Research in Pharmaceutical Economics", Associate Editor, 2003
- Reviewer, National Research Council of South Africa, 2003
- American Enterprise Institute, Health Advisory Board, 1999-2003
- Triangle Pharmaceuticals, Board of Directors, 2000-2003
- American Council on Science and Health, Board of Scientifiic Advisors, 2000-2003
- Journal of Law and Economics, Journal of Health Economics, Health Affairs, Economic Inquiry, and Rand Journal, Journal reviewer, 1999-2003
- Institute of Medicine Studies on Vaccine Policy and Bioterrorism, Outside reviewer, 2002
- Institute of Medicine Study of Vaccine Policy, Outside Reviewer, 2003
- Health Affairs, Economic Inquiry, Health Economics, PharmcoEconomics, Quarterly Review of Economics and Finance, and the Journal of Health Economics, Journal reviews, 2003
- Other
- Member, Board of Scientific Advisors, American Council on Science and Health, present
- Associate Editor, Journal of Research in Pharmaceutical Economics, present
- Adjunct Scholar and Advisory Board Member, Health Policy Research, present
- Program in Pharmaceuticals and Health Economics, Program Director, 1983-2003
- Member, Committee on Public-Private Sector Relations in Vaccine Innovation, Institute of Medicine, National Academy of Sciences, 1983-1985
- Advisory Panel Member, Office of Technology Assessment, The Patent System and Its Assessment on New Technological Enterprises,, 1982-1983
- Study Rapporteur, National Academy of Science Committee on Technology International Economic and Trade Issues, "The Impact of Government Regulation on Innovation", 1978-1979
- Consultant, Federal Trade Commission project, "The Effects of Repealing Anti-Substitution Laws on Drug Innovation", 1977-1978
- Selected Recent Invited Talks
- Columbia University, New York, NY, 11 December 2003
- Georgetown University, Washington, DC, 1 October 2003
- St. Vincent's University, Lathrobe, PA, 24 September 2003
- Keio University, Tokyo, Japan, 8 September 2003
- American Economic Association Meetings, Washington, DC, 5 January 2003
- Federal Reserve Bank of Dallas, Dallas, TX, 19 April 2002
- American Association for Advancement of Science, Boston, MA, 1 February 2002
- Robert Wood Johnson Foundation Colloquium, Washington, DC, 28 March 2001
- American Enterprise Institute, Washington, DC, 6 October 2000
- Schumpeterian Society Meetings, Manchester, UK, 30 June 2000
- US House of Representatives, Washington, DC, 29 June 1999
- "International Patent Policies and Pharmaceutical Innovation", University of Vienna, May 1996
- "Pharmaceutical Innovation, Cost-Effectiveness Research and Emerging Regulatory Issues", American Enterprise Institute, Washington, D.C., November 1996
- "Public Policies and Pharmaceutical Innovation", Jagellion University, Karkow, Poland, May 1996
- "The Effects of the Waxman Hatch Act on Drug Innovation and Generic Competition", Testimony before the U.S. Senate Judiciary Committee, March 1996
- "The Effects of Increased Government Purchases on Vaccine R&D", Testimony before the Subcommittee on Health and the Environment on the Vaccines for Children's Program, June 1995
- "Health Reform and Pharmaceutical Innovation", American Enterprise Institute, Washington, D.C., July 1994
- "R&D Costs, Innovational Output and Firm Size", Yale University Festschrift Honoring Merton J. Peck, New Haven, Connecticut, September 1994
- "Socially Optimal Reimbursement and Utilization Policies for Pharmaceuticals", Hungarian National Social Insurance Administration, Budapest, Hungary, April 1994
- "The Administration's Health Reform Plan--Implications for Pharmaceutical Innovation", testimony before Congressman Waxwan's House Subcommittee on Health and the Environment, February 1994
- "International Competition in Pharmaceutical R&D", National Science Board on Industrial Support for R&D, U.S. National Science Foundation, Washington, D.C., January 1991
- "Pharmaceutical Research and Development: Returns and Risk", Centre for Medicines Research Annual Lecture 1991, Royal College of Physicians, London, England, July 1991
- Testimony before the U.S. Senate Committee on the Judiciary in reference to The Patent Term Restoration Act of 1981 - S. 255, April 1981
Last modified: 2026/01/13
|
